Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company focused on investigational therapies for neurodegenerative and endocrine diseases, and its news flow reflects the progress and setbacks typical of clinical-stage drug development. Company updates frequently highlight milestones in its pipeline, including avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis (ALS), and AMX0318 as a long-acting GLP-1 receptor antagonist candidate.
Investors following AMLX news can expect regular announcements on clinical trial progress, such as enrollment status, early safety and tolerability data, and biomarker analyses from studies like the Phase 3 LUCIDITY trial in PBH and the Phase 1 LUMINA trial in ALS. Amylyx also issues press releases when it reports financial results, providing context on research and development spending, cash runway, and the anticipated timing of key clinical and regulatory milestones.
Another recurring news theme is regulatory and program updates, including FDA designations, decisions to advance or discontinue specific programs, and detailed descriptions of conditions such as PBH, ALS, PSP, and Wolfram syndrome. The company has, for example, communicated its decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results, while continuing development of AMX0035 in Wolfram syndrome.
Amylyx also announces capital markets events and investor outreach, such as underwritten public offerings of common stock and participation in healthcare and biopharma conferences. For readers tracking AMLX, this news page offers a consolidated view of clinical, financial, and strategic disclosures that shape the company’s development trajectory. Bookmarking this feed can help investors and observers monitor how Amylyx’ investigational therapies advance through trials and how management communicates key developments.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced that Co-CEOs Joshua Cohen and Justin Klee will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00am ET. The conference will be held virtually, and a live webcast of their presentation will be available in the 'Events' section of the company's website. A replay will be accessible for 90 days post-event. Amylyx is focused on developing innovative treatments for neurodegenerative diseases, with operations based in Cambridge, Massachusetts, and across Canada and EMEA.
Amylyx Pharmaceuticals has completed enrollment for the Phase 3 clinical trial, PHOENIX, evaluating AMX0035 for treating amyotrophic lateral sclerosis (ALS). This global, placebo-controlled study enrolled 664 participants and aims to assess the treatment's safety and efficacy over 48 weeks. Topline results are expected in 2024. The trial builds on positive outcomes from the prior Phase 2 CENTAUR trial, which demonstrated significant functional benefits and potential survival advantages. The European Medicines Agency is currently reviewing the marketing application for AMX0035, with a decision anticipated in early 2023.
Amylyx Pharmaceuticals (NASDAQ: AMLX) will have Co-CEOs Joshua Cohen and Justin Klee participate in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 3:05 p.m. ET. The conference will take place virtually, and a live webcast can be accessed on the company's investor relations website. A replay will be available for 90 days post-event. Amylyx Pharmaceuticals is dedicated to innovating treatments for the neurodegenerative community and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals (AMLX) announced significant updates, including the FDA approval and commercial launch of RELYVRIO™ for ALS treatment in the U.S. and the ongoing launch of ALBRIOZA™ in Canada. For Q3 2022, net product revenue reached $0.3 million, primarily from ALBRIOZA sales. Research and development expenses surged to $24.9 million, and general expenses rose to $29.9 million. The net loss was $53.8 million, or $0.92 per share. Cash reserves stood at $162.6 million after an upsized public offering raised $230.8 million.
Amylyx Pharmaceuticals will announce its third quarter 2022 financial results on November 10, 2022, after U.S. market close. The management team will hold a conference call at 4:30 p.m. ET to discuss the results and company updates. Investors can access the call by dialing either (877) 870-4263 for local or (412) 317-0790 for international attendees. A live audio webcast will also be available on the company's investor website, with an archive accessible for 90 days.
Amylyx Pharmaceuticals announced the successful completion of its upsized public offering, raising $246.3 million through the sale of 7,697,812 shares at $32.00 each. The offering included the full exercise of an option for an additional 1,004,062 shares. The funds generated will support the company's efforts in developing innovative treatments for the neurodegenerative community. The offering was managed by a consortium of financial firms, including Goldman Sachs and BofA Securities.
Amylyx Pharmaceuticals has announced an upsized public offering of 6,693,750 shares of common stock, priced at $32.00 per share, expected to generate gross proceeds of $214.2 million. The offering is set to close around October 11, 2022, pending customary conditions. The company has granted underwriters a 30-day option for an additional 1,004,062 shares. Goldman Sachs, BofA Securities, SVB Securities, and Evercore ISI are the joint book-running managers of the offering. Registration statements became effective on October 6, 2022.
Amylyx Pharmaceuticals has announced a public offering of 6,000,000 shares of common stock under an S-1 registration statement filed with the SEC. The company plans to offer all shares and may grant underwriters a 30-day option to purchase an additional 900,000 shares. The offering is subject to market conditions and may not be completed as anticipated. Goldman Sachs, BofA Securities, SVB Securities, and Evercore ISI are acting as joint book-running managers.
Amylyx Pharmaceuticals announced that the FDA has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for treating adults with amyotrophic lateral sclerosis (ALS).
RELYVRIO significantly slowed physical function loss in clinical trials, offering hope for approximately 29,000 ALS patients in the U.S. with median survival from diagnosis of 2-3 years. The drug is expected to be accessible through specialty pharmacies within 4-6 weeks. Amylyx plans to support ALS patients with a dedicated care team.
Amylyx Pharmaceuticals announced that clinical data from the placebo group of the CENTAUR trial for AMX0035 are now accessible in the PRO-ACT database. This initiative supports the ALS research community by enabling collaborative efforts to uncover new treatment pathways. The PRO-ACT platform, awarded for its innovation, contains data from over 11,600 ALS participants and has been essential for numerous publications. AMX0035, under evaluation for ALS, aims to reduce neuronal cell death.